Evanson Asset Management LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Evanson Asset Management LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 13.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,048 shares of the biopharmaceutical company’s stock after selling 2,523 shares during the period. Evanson Asset Management LLC’s holdings in Pfizer were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. RB Capital Management LLC increased its stake in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. raised its position in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the period. United Bank grew its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC increased its stake in Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp lifted its position in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after buying an additional 79,887 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Truist Financial reduced their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Price Performance

Pfizer stock traded down $0.03 during mid-day trading on Thursday, hitting $27.75. 39,620,254 shares of the company were exchanged, compared to its average volume of 43,835,094. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $157.14 billion, a PE ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The business has a fifty day moving average of $27.46 and a 200 day moving average of $29.46. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.